Pediatrix Medical Group, Inc. (NYSE:MD) Given Average Rating of “Hold” by Analysts

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have received an average rating of “Hold” from the six research firms that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $17.08.

A number of brokerages have commented on MD. StockNews.com upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday, January 22nd. Truist Financial boosted their price target on Pediatrix Medical Group from $15.00 to $18.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. UBS Group boosted their price target on Pediatrix Medical Group from $16.50 to $18.50 and gave the stock a “neutral” rating in a research note on Friday, February 21st. Mizuho boosted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Finally, Macquarie initiated coverage on Pediatrix Medical Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $18.00 price target on the stock.

Pediatrix Medical Group Price Performance

Shares of Pediatrix Medical Group stock opened at $13.71 on Friday. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $17.67. The stock has a market capitalization of $1.18 billion, a P/E ratio of -11.42, a PEG ratio of 1.74 and a beta of 1.48. The company has a current ratio of 1.60, a quick ratio of 1.42 and a debt-to-equity ratio of 0.81. The business’s fifty day moving average price is $14.16 and its 200 day moving average price is $13.41.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.12. The company had revenue of $502.36 million for the quarter, compared to analysts’ expectations of $486.22 million. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. As a group, research analysts anticipate that Pediatrix Medical Group will post 1.38 earnings per share for the current year.

Institutional Trading of Pediatrix Medical Group

A number of hedge funds have recently bought and sold shares of the company. State Street Corp increased its holdings in Pediatrix Medical Group by 1.4% in the third quarter. State Street Corp now owns 3,540,791 shares of the company’s stock worth $41,038,000 after buying an additional 50,597 shares during the last quarter. Nordea Investment Management AB lifted its position in Pediatrix Medical Group by 51.6% in the fourth quarter. Nordea Investment Management AB now owns 263,633 shares of the company’s stock worth $3,504,000 after purchasing an additional 89,739 shares during the period. Barclays PLC lifted its position in Pediatrix Medical Group by 302.9% in the third quarter. Barclays PLC now owns 142,087 shares of the company’s stock worth $1,646,000 after purchasing an additional 106,817 shares during the period. Franklin Resources Inc. bought a new position in Pediatrix Medical Group in the third quarter worth $598,000. Finally, Principal Financial Group Inc. lifted its position in Pediatrix Medical Group by 14.1% in the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock worth $5,953,000 after purchasing an additional 63,581 shares during the period. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.